ERBB2 and breast cancer: We first considered pathological subtypes, namely estrogen receptor-positive/HER2 negative (ER + /HER2-; n = 606 patients, 66%), HER2 + (n = 157 patients, 17%) and triple negative (n = 165 patients, 17%) early breast cancer (eBC).